← SynDRA
CATEQUENTINIB
SynDRA canonical compound SYN0039838 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | KDR | PDGFRB |
|---|
| Mechanism of action | PDGFR tyrosine kinase receptor inhibitor | VEGFR inhibitor |
|---|
All known targets
- KDR
- FLT4
- PDGFRB
- KIT
- FGFR1
- FLT1
- SRC
Mechanisms of action (all sources)
- KDR INHIBITOR
- Vascular endothelial growth factor receptor 2 inhibitor
- FLT4 INHIBITOR
- Vascular endothelial growth factor receptor 3 inhibitor
- KIT INHIBITOR
- Stem cell growth factor receptor inhibitor
- PDGFRB INHIBITOR
- Platelet-derived growth factor receptor beta inhibitor
- FGFR1 INHIBITOR
- FLT1 INHIBITOR
- PDGFR tyrosine kinase receptor inhibitor
- VEGFR inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- KSYK
- NSD2
- PDGFRA
- SYK
- VGFR1
Cross-references
Synonyms
- AL-3818
- Anlotinib
- AL3818
- UNII-GKF8S4C432
- GKF8S4C432
- AL 3818
- SCHEMBL2063386
- GTPL9601
- KSMZEXLVHXZPEF-UHFFFAOYSA-N
- MolPort-044-567-604
- ZINC117924202
- AKOS030526233
- DB11885
- CS-5396
- HY-19716
- 1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine
- 1-((4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropan-amine
- Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-
- RefChem:112849
- Anlotinib?
- CATEQUENTINIB [INN]
- Catequentinib (USAN/INN)
- CATEQUENTINIB [USAN]
- CATEQUENTINIB [WHO-DD]
- SCHEMBL29364137
- SCHEMBL29379727
- SCHEMBL29383986
- BDBM734434
- GLXC-10628
- EX-A2427
- ISB15690
- NSC832523
- NSC-832523
- SB19798
- US20250129067, Compound Anlotinib
- NS00073391
- C13643
- D12526
Look up CATEQUENTINIB in the interactive SynDRA portal →